Patients demographics and clinical characteristics
| . | No. . | % . |
|---|---|---|
| Patients no. | 40 | |
| Sex | ||
| Male | 22 | 55 |
| Female | 18 | 45 |
| MGUS no. | 11 | 27 |
| Median age, y (range) | 65 | (44-78) |
| Type | ||
| Heavy chain leading∗1 | 10 | 91 |
| Light chain leading∗2 | 1 | 9 |
| FISH | ||
| Standard risk | 3 | 27 |
| High risk§ | 2 | 18 |
| Missing | 6 | 55 |
| Mean CRP, mg/dL (range) | 0.65 | (0.1-2.8) |
| Documented SMM progression | 2 | 18 |
| SMM no. | 7 | 18 |
| Median age, y (range) | 60 | (51-80) |
| Type | ||
| Heavy chain leading∗3 | 6 | 86 |
| Light chain leading∗4 | 1 | 14 |
| FISH | ||
| Standard risk | 4 | 57 |
| High risk | 3 | 43 |
| Missing | 0 | 0 |
| Mean CRP, mg/dL (range) | 0.4 | (0.1-1.0) |
| Documented MGUS pre-phase | 2 | 29 |
| Documented MM progression | 5 | 71 |
| MM no. | 22 | 55 |
| Median age, y (range) | 58 | (50-76) |
| Type/Paraprotein | ||
| Heavy chain leading∗5 | 18 | 82 |
| Light chain leading∗6 | 4 | 18 |
| CRAB (see below) | ||
| Hyper calcaemia | 1 | 5 |
| Renal failure | 3 | 14 |
| Anaemia∗ | 8 | 36 |
| Bone lesions | 17 | 77 |
| SLiM CRAB (see below) | ||
| Sixty-percent bone marrow plasma cells† | 11 | 50 |
| Light chain ratio ≥100 | 6 | 27 |
| >1 focal lesions on MRI studies | 1 | 5 |
| FISH | ||
| Standard risk | 11 | 50 |
| High risk | 9 | 41 |
| Missing | 2 | 9 |
| Mean CRP, mg/dL (range) | 0.56 | (0.1-3.7) |
| Documented SMM or MGUS pre-phase | 8 | 36 |
| . | No. . | % . |
|---|---|---|
| Patients no. | 40 | |
| Sex | ||
| Male | 22 | 55 |
| Female | 18 | 45 |
| MGUS no. | 11 | 27 |
| Median age, y (range) | 65 | (44-78) |
| Type | ||
| Heavy chain leading∗1 | 10 | 91 |
| Light chain leading∗2 | 1 | 9 |
| FISH | ||
| Standard risk | 3 | 27 |
| High risk§ | 2 | 18 |
| Missing | 6 | 55 |
| Mean CRP, mg/dL (range) | 0.65 | (0.1-2.8) |
| Documented SMM progression | 2 | 18 |
| SMM no. | 7 | 18 |
| Median age, y (range) | 60 | (51-80) |
| Type | ||
| Heavy chain leading∗3 | 6 | 86 |
| Light chain leading∗4 | 1 | 14 |
| FISH | ||
| Standard risk | 4 | 57 |
| High risk | 3 | 43 |
| Missing | 0 | 0 |
| Mean CRP, mg/dL (range) | 0.4 | (0.1-1.0) |
| Documented MGUS pre-phase | 2 | 29 |
| Documented MM progression | 5 | 71 |
| MM no. | 22 | 55 |
| Median age, y (range) | 58 | (50-76) |
| Type/Paraprotein | ||
| Heavy chain leading∗5 | 18 | 82 |
| Light chain leading∗6 | 4 | 18 |
| CRAB (see below) | ||
| Hyper calcaemia | 1 | 5 |
| Renal failure | 3 | 14 |
| Anaemia∗ | 8 | 36 |
| Bone lesions | 17 | 77 |
| SLiM CRAB (see below) | ||
| Sixty-percent bone marrow plasma cells† | 11 | 50 |
| Light chain ratio ≥100 | 6 | 27 |
| >1 focal lesions on MRI studies | 1 | 5 |
| FISH | ||
| Standard risk | 11 | 50 |
| High risk | 9 | 41 |
| Missing | 2 | 9 |
| Mean CRP, mg/dL (range) | 0.56 | (0.1-3.7) |
| Documented SMM or MGUS pre-phase | 8 | 36 |
Scatter Plot for Infiltration [%], Scatter Plot for hemoglobin (HB) [g/dl] of MGUS, SMM and MM patients included in this study at time of diagnosis shown on the right side.
MGUS, monoclonal gammopathy of undetermined significance; SMM, smoldering myeloma; MM, multiple myeloma; CRP, C-reactive protein; FISH, fluorescence in situ hybridization.
∗1IgG kappa n = 7, IgG lambda n = 2, IgM lambda n = 1.
∗2LC kappa n = 1.
∗3IgG kappa n = 3, IgG lambda n = 2, IgA kappa n = 1.
∗4LC kappa n = 1.
∗5IgG kappa n = 9, IgG lambda n = 4, IgA kappa n = 3, IgA lambda n = 1, IgG lambda n = 1.
∗6LC kappa n = 3, LC lambda n = 1.
Plot shows the HB values of the individual patients.
Plot shows the infiltration rate by plasma cells of the individual patients.
According to revised-international staging score and International Myeloma Working Group: del(17p), t(4;14), t(14;16), +1q21.